Notice ID: de23b075837246478ebc3b18a9230403Solicitation
A--Biologic Specimen and Data Repositories Informatio
Archived on April 18, 2026. Solicitation posted by HEALTH AND HUMAN SERVICES, DEPARTMENT OF (NATIONAL INSTITUTES OF HEALTH) on March 24, 2026. Solicitation 75N92026R00007.
NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology)). Set-aside: Total Small Business Set-Aside (FAR 19.5). Original response deadline: . Full description on SAM.gov.
Description
Biologic Specimen and Data Repositories Information Coordinating Center (BioLINCC)
Overview
Agency:
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Office:NATIONAL INSTITUTES OF HEALTH NHLBI
Posted:March 24, 2026
NAICS:541714: Research and Development in Biotechnology (except Nanobiotechnology)
Last Updated:Aug 21, 2026
PSC:AN11: HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH
Response Deadline:
Set-Aside:Total Small Business Set-Aside (FAR 19.5)
Type:Solicitation
Place of Performance:Not specified
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Documents
No documents available.
Lifecycle
Solicitation:
75N92026R00007- Market Research
- Pre-Solicitation
- Solicitation
Award typically follows within 30–90 days after the response deadline. (estimate)
- Market ResearchDec 5, 2025
A--Biologic Specimen and Data Repositories Information Coordinating Center (BioLIN
- 4×SolicitationCurrentFeb 11, 2026
A--Biologic Specimen and Data Repositories Informatio
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
SOURCES SOUGHT NOTICE Title: Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories Agency: National Institutes of Health (NIH) Description This is a SMALL BUSINESS SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code 541714 should not submit a response to this notice. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. Purpose NIH is seeking information from qualified R&D firms, small businesses, and subcontractors regarding their capabilities to support the operation, consolidation, and/or recompete of one or more NIH-funded biorepositories for FY 2028, including at a minimum the NIDA Center for Genetic Studies (NCGS) and the NIH Brain Development Cohorts (NBDC) Biobank, which supports the Adolescent Brain Cognitive Development (ABCD) Study, and HEALthy Brain and Child Development (HBCD) Study. This notice also serves to determine the availability of all small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses) with the capability to perform this work. Background NIH currently supports over 20 biorepositories across 10+ Institutes and Centers, with each individual biorepository storing several thousands to over 3.5 million samples. NIH biorepositories have stored, analyzed, and distributed millions of samples of biomaterials to enable broad investigations into the myriad of biological and environmental factors that affect health, development, and disease. These repositories typically: Receive, process, store, and biosamples from a wide range of biospecimen types (e.g. blood/derivatives, fluids, DNA/RNA, hair, cell lines, iPSCs, teeth, fecal matter, birth specimens and other tissues such as brain and other organs) at various temperature and storage conditions (e.g. -80C, liquid nitrogen; fresh, frozen, paraffin-embedded, formalin-fixed) at scales ranging from tens of thousands to several million specimens. Serve dozens to hundreds of research studies across the United States and abroad. Enable broad, controlled-access biomaterial sharing to meet specific research objectives that further our knowledge of health Anticipate continued growth in biospecimen and data volume over the life of the award. Scope of Work & Required Capabilities Capable vendors should provide examples from current or previous projects when responding to capabilities. A. Sample Management and Storage Maintain secure, humidity- and temperature-controlled storage and tracking for at least 3,500,000 biospecimens in accordance with Best Practices, Clinical and Laboratory Standards, and Good Laboratory Practice (GLP; 21 CFR 58) with expert quality control and assurance procedures. Document the maximum capacity that could be achieved to expand storage beyond the minimum requested. Destroy samples per regulatory and consent requirements when no longer needed. College of American Pathologists (CAP) Biorepository Accreditation preferred. Maintain positive chain of custody and resolve data/sample discrepancies (missing data, incorrect information, misdirected samples) through issue tracking and resolution, coordinating with relevant receiving/data management teams (e.g. sites, site monitors, study staff). Receive de-identified clinical, diagnostic, environmental, and phenotypic data alongside biospecimens from funded grants/contracts. Centrally manage and cost-effectively distribute biosamples to qualified investigators approved through established access programs. Provide studies with collection kits and supplies, including barcoded tubes with human-readable labels. Provide research staff training for ordering supplies and collecting samples. B. Data Curation and Management Develop and maintain SOPs for sample receipt, storage, processing, QC, and distribution. Receive de-identified clinical, diagnostic, environmental, and phenotypic data associated with biospecimens from funded grants/contracts. Maintain an internal relational database (e.g., using persistent identifiers such as RRIDs) linked to associated data and participant and sample identifiers, with computerized inventory management and accurate tracking of sample and data location. Register and track biospecimens via an internal relational database with sample IDs (RRID) linked to participant IDs and associated data in the Contractor's auditable LIMS, with computerized inventory management and accurate tracking of sample/data location. Clean, standardize, and harmonize clinical data with cross-disorder phenotypic knowledge (e.g. different diagnostic systems or criteria, such as RDOC, DSM, ICD), incorporating data from electronic health records when applicable. Transfer data and sample IDs to controlled-access repositories or Data Centers (e.g., dbGAP, NBDC Data Hub or program specific data repositories). C. Laboratory and Analytic Capabilities Demonstrate laboratory expertise appropriate to the repository's sample types, which may include molecular biology techniques (e.g., DNA/RNA extraction, cell line transformation/immortalization), rigorous quality control, and tissue/cell culture (isolation, scale-up, and banking of primary cells). Provide CLIA-certification status. Provide laboratory capabilities for, but not limited to: metabolic, hematologic, and/or clinical assays high-throughput genotyping, sequencing, and gene-expression analysis Mass spectrometry for proteomics and metabolomics Advanced genomic and cellular techniques such as short- and long-range sequencing, chromatin capture, ChIP-seq, Cut-and-Tag, HiC generation of iPSC/neural stem cell lines CRISPR/Cas9 gene editing Analysis of RNA and DNA from Formalin-Fixed Parafin-Embedded tissue Provide scientific and technical expertise to evaluate and respond to researcher-submitted requests for biospecimen availability. Demonstrate that lead investigators and support staff have relevant experience in biobanking, LIMS, and database management Store and/or process histopathological tissue samples. Isolate, scale up, and bank primary cells from diverse tissue samples. D. Informatics Requirements and Cyberinfrastructure Develop, or manage and enhance (if already existing), a biorepository web portal (front-end and back-end), supporting existing features and providing updates/improvements as requested, potentially including: Synchronizing sample availability data with a public- or investigator-facing sample explorer tool to streamline discovery of related data and biospecimens across repositories Showcase published research and provide lay summaries Advertise repository resources For existing resources, support all currently available features, with updates and improvements as requested Where in scope, develop outreach tools (e.g., an integrated chatbot or public-facing portal) to help users locate biomaterials/data and discover related resources across repositories Develop or maintain backend infrastructure (e.g., server maintenance, microservices, relational databases such as PostgreSQL) and front-end website design/UI-UX. Maintain Authority to Operate (ATO) and require security documentation to keep systems compliant with applicable FISMA-level and other NIH requirements. Maintain, update, and develop Application Programming Interfaces (APIs) and cyberinfrastructure for secure, interoperable data exchange. Capabilities for homomorphic encryption and distributed learning. Demonstrate experience and technical expertise to address all aspects of informatics requirements listed above. K. Collaboration & Governance Establish a strong collaborative relationship with the NIH Data Centers, study teams, and Institutes/Centers to enable modifications as the studies evolve. Serve as a co-signatory of the Specimen/Material Transfer Agreements developed by the funding Institute/Center. Be eligible to receive a Certificate of Confidentiality, adhering to requirements for protecting sensitive participant information as set forth in 45 CFR Part 75.303(a), NIHGPS Chapter 8.3 and 15.2.1, and subsection 301(d) of the Public Health Service Act (see: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html). Comply with all applicable human subjects protection, ethical, privacy, and data security regulations. Submission Requirements Interested organizations must demonstrate and document in a submitted capability statement extensive experience across the technical areas above, and include specific information on: Experience — An outline of previous similar projects, specifically the techniques employed in the areas described above. Personnel — Name and professional qualifications of personnel with specific experience in the work requested and knowledge of/experience in biomedical research. Facilities — Availability and description of facilities and equipment required to conduct this type of work. The Government will assess the appropriateness of professional and technical personnel classifications and consider any other specific and relevant information that would improve evaluation of respondents. Organizations should demonstrate capability to administer and coordinate interrelated tasks effectively and in a timely manner. Supporting documentation may include contracts in which the organization performed equivalent tasks (Government and commercial), references (names, titles, phone numbers, and other identifying information), and awards or commendations. An organization that does not have all the listed expertise, may respond by listing organizations with which they intend to collaborate or have as subcontractors to fulfill the requirements. Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than October 20, 2026 at 1:00 PM EST. All capability statements should include: Company name and address Point of contact SAM.gov Unique Entity Identifier (UEI) Phone/fax/email NAICS Code(s) Business size and status Capability information responsive to the requirements and qualifications identified in this notice Type(s) of business, if any (e.g., small, Veteran-owned, service-disabled Veteran-owned, women-owned, 8(a), Small Disadvantaged Business (SDB), Historically Underutilized Business Zone (HUBZone)) NAICS Code: 541714 — Research and Development in Biotechnology (except Nanobiotechnology). SBA size standard: 1,000 employees or fewer. Submission Instructions Capability statements must be submitted electronically to: Shaun Rostad, Contract Specialist Email: shaun.rostad@nih.gov Secondary Point of Contact: Joshua T. Lazarus, Contract Specialist Email: josh.lazarus@nih.gov Submissions are due NO LATER THAN 1:00 p.m. EST on October 20, 2026. The subject line must include the Small Business Sources Sought Number. NIDA will not accept paper or faxed capability statements. Disclaimer THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement, nor does it constitute a solicitation or commitment by NIDA. The Government does not intend to award a contract based on responses under this announcement, nor otherwise pay for the preparation of any information submitted. Any proprietary information should be so marked. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Respondents should ensure their response is complete and sufficiently detailed to allow the Government to determine qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of information or provide feedback with respect to any information submitted. Based on the Government’s market research, it is the agency’s assessment that the services described herein do not appear to constitute commercial services as defined under RFO Subpart 2.1, and therefore, the agency does not currently intend to utilize RFO Part 12 Acquisition Procedures. However, if an interested party asserts that these services are in fact commercial in nature, it should respond to this requirement and provide supporting evidence demonstrating that the services meet the definition of commercial services as prescribed by the applicable regulations. | Market Research | 541714 | Total Small Business Set-Aside | 10/01/2026 | 10/20/2026 | - | |
SOURCES SOUGHT NOTICE Title: Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories Agency: National Institutes of Health (NIH) Description This is a SMALL BUSINESS SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses); (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) whether commercials sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code 541714 should not submit a response to this notice. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. Purpose NIH is seeking capability statements from small businesses, and subcontractors regarding their abilities to continue the work of the NIDA Center for Genetic Studies (NCGS) and the NIH Brain Development Cohorts (NBDC) Biobank, which supports the Adolescent Brain Cognitive Development (ABCD) Study, and HEALthy Brain and Child Development (HBCD) Study. This notice also serves to determine the availability of all small businesses (e.g., 8(a), Veteran-owned small businesses, service-disabled Veteran-owned small businesses, HUBZone small businesses, small disadvantaged businesses, and women-owned small businesses) with the capability to perform this work. Background NIH currently supports over 20 biorepositories across 10+ Institutes and Centers, with each individual biorepository storing several thousands to over 3.5 million samples. NIH biorepositories have stored, analyzed, and distributed millions of samples of biomaterials to enable broad investigations into the myriad of biological and environmental factors that affect health, development, and disease. These repositories typically: Receive, process, store, and biosamples from a wide range of biospecimen types (e.g. blood/derivatives, fluids, DNA/RNA, hair, cell lines, iPSCs, teeth, fecal matter, birth specimens and other tissues such as brain and other organs) at various temperature and storage conditions (e.g. -80C, liquid nitrogen; fresh, frozen, paraffin-embedded, formalin-fixed) at scales ranging from tens of thousands to several million specimens. Serve dozens to hundreds of research studies across the United States and abroad. Enable broad, controlled-access biomaterial sharing to meet specific research objectives that further our knowledge of health Anticipate continued growth in biospecimen and data volume over the life of the award. Scope of Work & Required Capabilities Capable vendors should provide examples from current or previous projects when responding to capabilities. A. Sample Management and Storage Maintain secure, humidity- and temperature-controlled storage and tracking for at least 3,500,000 biospecimens in accordance with Best Practices, Clinical and Laboratory Standards, and Good Laboratory Practice (GLP; 21 CFR 58) with expert quality control and assurance procedures. Document the maximum capacity that could be achieved to expand storage beyond the minimum requested. Destroy samples per regulatory and consent requirements when no longer needed. College of American Pathologists (CAP) Biorepository Accreditation preferred. Maintain positive chain of custody and resolve data/sample discrepancies (missing data, incorrect information, misdirected samples) through issue tracking and resolution, coordinating with relevant receiving/data management teams (e.g. sites, site monitors, study staff). Receive de-identified clinical, diagnostic, environmental, and phenotypic data alongside biospecimens from funded grants/contracts. Centrally manage and cost-effectively distribute biosamples to qualified investigators approved through established access programs. Provide studies with collection kits and supplies, including barcoded tubes with human-readable labels. Provide research staff training for ordering supplies and collecting samples. B. Data Curation and Management Develop and maintain SOPs for sample receipt, storage, processing, QC, and distribution. Receive de-identified clinical, diagnostic, environmental, and phenotypic data associated with biospecimens from funded grants/contracts. Maintain an internal relational database (e.g., using persistent identifiers such as RRIDs) linked to associated data and participant and sample identifiers, with computerized inventory management and accurate tracking of sample and data location. Register and track biospecimens via an internal relational database with sample IDs (RRID) linked to participant IDs and associated data in the Contractor's auditable LIMS, with computerized inventory management and accurate tracking of sample/data location. Clean, standardize, and harmonize clinical data with cross-disorder phenotypic knowledge (e.g. different diagnostic systems or criteria, such as RDOC, DSM, ICD), incorporating data from electronic health records when applicable. Transfer data and sample IDs to controlled-access repositories or Data Centers (e.g., dbGAP, NBDC Data Hub or program specific data repositories). C. Laboratory and Analytic Capabilities Demonstrate laboratory expertise appropriate to the repository's sample types, which may include molecular biology techniques (e.g., DNA/RNA extraction, cell line transformation/immortalization), rigorous quality control, and tissue/cell culture (isolation, scale-up, and banking of primary cells). Provide CLIA-certification status. Provide laboratory capabilities for, but not limited to: metabolic, hematologic, and/or clinical assays high-throughput genotyping, sequencing, and gene-expression analysis Mass spectrometry for proteomics and metabolomics Advanced genomic and cellular techniques such as short- and long-range sequencing, chromatin capture, ChIP-seq, Cut-and-Tag, HiC generation of iPSC/neural stem cell lines CRISPR/Cas9 gene editing Analysis of RNA and DNA from Formalin-Fixed Parafin-Embedded tissue Provide scientific and technical expertise to evaluate and respond to researcher-submitted requests for biospecimen availability. Demonstrate that lead investigators and support staff have relevant experience in biobanking, LIMS, and database management Store and/or process histopathological tissue samples. Isolate, scale up, and bank primary cells from diverse tissue samples. D. Informatics Requirements and Cyberinfrastructure Develop, or manage and enhance (if already existing), a biorepository web portal (front-end and back-end), supporting existing features and providing updates/improvements as requested, potentially including: Synchronizing sample availability data with a public- or investigator-facing sample explorer tool to streamline discovery of related data and biospecimens across repositories Showcase published research and provide lay summaries Advertise repository resources For existing resources, support all currently available features, with updates and improvements as requested Where in scope, develop outreach tools (e.g., an integrated chatbot or public-facing portal) to help users locate biomaterials/data and discover related resources across repositories Develop or maintain backend infrastructure (e.g., server maintenance, microservices, relational databases such as PostgreSQL) and front-end website design/UI-UX. Maintain Authority to Operate (ATO) and require security documentation to keep systems compliant with applicable FISMA-level and other NIH requirements. Maintain, update, and develop Application Programming Interfaces (APIs) and cyberinfrastructure for secure, interoperable data exchange. Capabilities for homomorphic encryption and distributed learning. Demonstrate experience and technical expertise to address all aspects of informatics requirements listed above. K. Collaboration & Governance Establish a strong collaborative relationship with the NIH Data Centers, study teams, and Institutes/Centers to enable modifications as the studies evolve. Serve as a co-signatory of the Specimen/Material Transfer Agreements developed by the funding Institute/Center. Be eligible to receive a Certificate of Confidentiality, adhering to requirements for protecting sensitive participant information as set forth in 45 CFR Part 75.303(a), NIHGPS Chapter 8.3 and 15.2.1, and subsection 301(d) of the Public Health Service Act (see: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html). Comply with all applicable human subjects protection, ethical, privacy, and data security regulations. Submission Requirements Interested organizations must demonstrate and document in a submitted capability statement extensive experience across the technical areas above, and include specific information on: Experience — An outline of previous similar projects, specifically the techniques employed in the areas described above. Personnel — Name and professional qualifications of personnel with specific experience in the work requested and knowledge of/experience in biomedical research. Facilities — Availability and description of facilities and equipment required to conduct this type of work. The Government will assess the appropriateness of professional and technical personnel classifications and consider any other specific and relevant information that would improve evaluation of respondents. Organizations should demonstrate capability to administer and coordinate interrelated tasks effectively and in a timely manner. Supporting documentation may include contracts in which the organization performed equivalent tasks (Government and commercial), references (names, titles, phone numbers, and other identifying information), and awards or commendations. An organization that does not have all the listed expertise, may respond by listing organizations with which they intend to collaborate or have as subcontractors to fulfill the requirements. Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than October 20, 2026 at 1:00 PM EST. All capability statements should include: Company name and address Point of contact SAM.gov Unique Entity Identifier (UEI) Phone/fax/email NAICS Code(s) Business size and status Capability information responsive to the requirements and qualifications identified in this notice Type(s) of business, if any (e.g., small, Veteran-owned, service-disabled Veteran-owned, women-owned, 8(a), Small Disadvantaged Business (SDB), Historically Underutilized Business Zone (HUBZone)) NAICS Code: 541714 — Research and Development in Biotechnology (except Nanobiotechnology). SBA size standard: 1,000 employees or fewer. Submission Instructions Capability statements must be submitted electronically to: Shaun Rostad, Contract Specialist Email: shaun.rostad@nih.gov Secondary Point of Contact: Joshua T. Lazarus, Contract Specialist Email: josh.lazarus@nih.gov Submissions are due NO LATER THAN 1:00 p.m. EST on October 20, 2026. The subject line must include the Small Business Sources Sought Number. NIDA will not accept paper or faxed capability statements. Disclaimer THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement, nor does it constitute a solicitation or commitment by NIDA. The Government does not intend to award a contract based on responses under this announcement, nor otherwise pay for the preparation of any information submitted. Any proprietary information should be so marked. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Respondents should ensure their response is complete and sufficiently detailed to allow the Government to determine qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of information or provide feedback with respect to any information submitted. Based on the Government’s market research, it is the agency’s assessment that the services described herein do not appear to constitute commercial services as defined under RFO Subpart 2.1, and therefore, the agency does not currently intend to utilize RFO Part 12 Acquisition Procedures. However, if an interested party asserts that these services are in fact commercial in nature, it should respond to this requirement and provide supporting evidence demonstrating that the services meet the definition of commercial services as prescribed by the applicable regulations. | Market Research | 541714 | Total Small Business Set-Aside | 09/28/2026 | 10/20/2026 | - | |
SPECIAL NOTICE — INTENT TO SOLE SOURCE Food and Drug Administration (FDA) Office of Acquisitions and Grants Services (OAGS) Acquisition Title: FY26–FY30 precisionFDA Platform Indefinite Delivery Indefinite Quantity (IDIQ) Acquisition Identification Number: ODT-2026-132021 NAICS Code: 541714 PSC Code: D319 (Cloud Computing) Set-Aside: Small Business (DNAnexus confirmed SB under NAICS 541714) Contract Type: Firm-Fixed-Price IDIQ Period of Performance: 08/10/2026 – 08/09/2030 Estimated Value: $33,000,000 Notice: The Food and Drug Administration (FDA), Office of Digital Transformation (ODT), Office of Data Analytics and Research (ODAR), Health Informatics Staff (HIS), intends to award a sole-source Indefinite Delivery Indefinite Quantity (IDIQ) contract to: DNAnexus, Inc. 1975 West El Camino Real, Suite 204 Mountain View, CA 94040 This action is being conducted under the authority of FAR 6.302-1 (Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements), pursuant to 41 U.S.C. 3304(a)(1). Description of Requirement: The FDA requires continued operations, sustainment, modernization, and cloud support for the precisionFDA platform — a FISMA-authorized, secure, cloud-based collaborative research environment for next-generation sequencing (NGS) assay evaluation, genomics and multi-omics research, and regulatory science applications. The platform supports collaboration between FDA researchers and reviewers, as well as external collaborators and sponsors across multiple FDA centers, including CDER, CBER, CDRH, CVM, and CFSAN. Services to be acquired include: Platform access licenses, cloud computing resources (compute, storage, data transfer on AWS), operations and maintenance, security patching, and technical support Continuation of all current precisionFDA capabilities, including immutable files with chain of provenance, file locking, Government-only spaces, Protected spaces, Review spaces, FHIR Stations, Scientific Challenge Framework, and custom data portal development capability Development and maintenance of the precisionFDA High (FISMA High) platform on FDA GovCloud FedRAMP Class C (Moderate) and FISMA High compliance maintenance per NIST SP 800-53 Rev5 Integration support for FDA enterprise systems including the Global Substance Registration System (GSRS) Training, user support, disaster recovery, and business continuity services Place of Performance: Contractor facility and FDA White Oak Campus, 10903 New Hampshire Avenue, Silver Spring, MD 20993 Basis for Sole Source Determination: Comprehensive market research was conducted in accordance with FAR Part 10, evaluating 20 vendors with a detailed assessment of 8 shortlisted vendors against 33 critical capability requirements. The research conclusively determined that DNAnexus is the only vendor capable of meeting FDA's requirements for Day-1 continuity of the precisionFDA mission on the date of contract award, for the following reasons: Only vendor with zero capability gaps: DNAnexus is the only vendor that scored fully across all 33 assessed capabilities. No alternative vendor can replicate on Day 1 the precisionFDA capabilities of immutable files with chain of provenance, file locking, Government-only spaces, Protected spaces, Review spaces, FHIR Stations, the Scientific Challenge Framework, or custom data portal development capability. Unique secure external collaboration capability: DNAnexus is the only platform provider able to facilitate secure FDA-sponsored scientific challenges and controlled communication with industry sponsors, vendors, academic researchers, and international regulatory partners while maintaining regulatory-grade confidentiality controls, data segregation, audit trails, and compliance features. Institutional knowledge and validated workflows: FDA has invested over seven years in developing, validating, and documenting bioinformatics workflows on the precisionFDA platform. Over 300 FDA scientific reviewers, bioinformaticians, and research scientists have been trained on the platform. The application library includes 100+ versioned apps. Migration to an alternative platform would require complete revalidation and an estimated $14.7M full rebuild. FedRAMP and FISMA compliance: DNAnexus holds FedRAMP Class C (Moderate) authorization (Cert ID FR1814557199, confirmed June 18, 2026) and FISMA Moderate ATO (FDA-sponsored). DNAnexus is actively enrolled in the PRISM High-Impact Platform Pilot (March 2026) providing a structured pathway to FedRAMP High authorization, with a parallel FISMA High ATO track to support the precisionFDA High platform. Small Business: DNAnexus is confirmed as a Small Business under NAICS 541714 (~277 employees; 1,000-employee size standard). Response Instructions: This notice is not a solicitation and does not commit the Government to award a contract. No award will be made solely on the basis of responses to this notice. Interested parties who believe they are capable of meeting the Government's requirements in their entirety may submit a written capability statement to the Contracting Officer no later than 15 calendar days from the date of this notice. Capability statements will be evaluated to determine whether full and open competition should be conducted in lieu of a sole-source award. Capability statements must address, at a minimum, the vendor's ability to provide Day-1 continuity of all current precisionFDA capabilities, FedRAMP Class C (Moderate) authorization status, and a demonstrated pathway to FISMA High authorization. Responses must be submitted electronically to: Steven Gagnon, Contracting Officer Email: Steven.Gagnon@fda.hhs.gov Allison Meads, Contract Specialist Email: Allison.Meads@fda.hhs.gov Subject Line: Capability Statement — precisionFDA IDIQ Sole Source Notice, ODT-2026-132021 Telephone responses will not be accepted. The Government is not responsible for any costs incurred in preparing a response to this notice. Point of Contact: Steven Gagnon, Contracting Officer Food and Drug Administration, Office of Acquisitions and Grants Services Email: Steven.Gagnon@fda.hhs.gov Allison Meads, Contract Specialist Email: Allison.Meads@fda.hhs.gov | Special Notice | 541714 | Total Small Business Set-Aside | 09/23/2026 | 10/09/2026 | - | |
SOURCES SOUGHT NOTICE – No. 75N98026R00175 Title: Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories Agency: National Institutes of Health (NIH) Description This is a SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources and (2) whether commercial sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. Purpose NIH is seeking information from qualified R&D firms, small businesses, and subcontractors regarding their capabilities to support the operation, consolidation, and/or recompete of one or more NIH-funded biorepositories for FY 2028, including at a minimum the NIDA Center for Genetic Studies (NCGS) and the NIH Brain Development Cohorts (NBDC) Biobank, which supports the Adolescent Brain Cognitive Development (ABCD) Study, and HEALthy Brain and Child Development (HBCD) Study. Background NIH currently supports over 20 biorepositories across 10+ Institutes and Centers, with each individual biorepository storing several thousands to over 3.5 million samples. NIH biorepositories have stored, analyzed, and distributed millions of samples of biomaterials to enable broad investigations into the myriad of biological and environmental factors that affect health, development, and disease. These repositories typically: Receive, process, store, and biosamples from a wide range of biospecimen types (e.g. blood/derivatives, fluids, DNA/RNA, hair, cell lines, iPSCs, teeth, fecal matter, birth specimens and other tissues such as brain and other organs) at various temperature and storage conditions (e.g. -80C, liquid nitrogen; fresh, frozen, paraffin-embedded, formalin-fixed) at scales ranging from tens of thousands to several million specimens. Serve dozens to hundreds of research studies across the United States and abroad. Enable broad, controlled-access biomaterial sharing to meet specific research objectives that further our knowledge of health Anticipate continued growth in biospecimen and data volume over the life of the award. Scope of Work & Required Capabilities Capable vendors should provide examples from current or previous projects when responding to capabilities. A. Sample Management and Storage Maintain secure, humidity- and temperature-controlled storage and tracking for at least 3,500,000 biospecimens in accordance with Best Practices, Clinical and Laboratory Standards, and Good Laboratory Practice (GLP; 21 CFR 58) with expert quality control and assurance procedures. Document the maximum capacity that could be achieved to expand storage beyond the minimum requested. Destroy samples per regulatory and consent requirements when no longer needed. College of American Pathologists (CAP) Biorepository Accreditation preferred. Maintain positive chain of custody and resolve data/sample discrepancies (missing data, incorrect information, misdirected samples) through issue tracking and resolution, coordinating with relevant receiving/data management teams (e.g. sites, site monitors, study staff). Receive de-identified clinical, diagnostic, environmental, and phenotypic data alongside biospecimens from funded grants/contracts. Centrally manage and cost-effectively distribute biosamples to qualified investigators approved through established access programs. Provide studies with collection kits and supplies, including barcoded tubes with human-readable labels. Provide research staff training for ordering supplies and collecting samples. B. Data Curation and Management Develop and maintain SOPs for sample receipt, storage, processing, QC, and distribution. Receive de-identified clinical, diagnostic, environmental, and phenotypic data associated with biospecimens from funded grants/contracts. Maintain an internal relational database (e.g., using persistent identifiers such as RRIDs) linked to associated data and participant and sample identifiers, with computerized inventory management and accurate tracking of sample and data location. Register and track biospecimens via an internal relational database with sample IDs (RRID) linked to participant IDs and associated data in the Contractor's auditable LIMS, with computerized inventory management and accurate tracking of sample/data location. Clean, standardize, and harmonize clinical data with cross-disorder phenotypic knowledge (e.g. different diagnostic systems or criteria, such as RDOC, DSM, ICD), incorporating data from electronic health records when applicable. Transfer data and sample IDs to controlled-access repositories or Data Centers (e.g., dbGAP, NBDC Data Hub or program specific data repositories). C. Laboratory and Analytic Capabilities Demonstrate laboratory expertise appropriate to the repository's sample types, which may include molecular biology techniques (e.g., DNA/RNA extraction, cell line transformation/immortalization), rigorous quality control, and tissue/cell culture (isolation, scale-up, and banking of primary cells). Provide CLIA-certification status. Provide laboratory capabilities for, but not limited to: metabolic, hematologic, and/or clinical assays high-throughput genotyping, sequencing, and gene-expression analysis Mass spectrometry for proteomics and metabolomics Advanced genomic and cellular techniques such as short- and long-range sequencing, chromatin capture, ChIP-seq, Cut-and-Tag, HiC generation of iPSC/neural stem cell lines CRISPR/Cas9 gene editing Analysis of RNA and DNA from Formalin-Fixed Parafin-Embedded tissue Provide scientific and technical expertise to evaluate and respond to researcher-submitted requests for biospecimen availability. Demonstrate that lead investigators and support staff have relevant experience in biobanking, LIMS, and database management Store and/or process histopathological tissue samples. Isolate, scale up, and bank primary cells from diverse tissue samples. D. Informatics Requirements and Cyberinfrastructure Develop, or manage and enhance (if already existing), a biorepository web portal (front-end and back-end), supporting existing features and providing updates/improvements as requested, potentially including: Synchronizing sample availability data with a public- or investigator-facing sample explorer tool to streamline discovery of related data and biospecimens across repositories Showcase published research and provide lay summaries Advertise repository resources For existing resources, support all currently available features, with updates and improvements as requested Where in scope, develop outreach tools (e.g., an integrated chatbot or public-facing portal) to help users locate biomaterials/data and discover related resources across repositories Develop or maintain backend infrastructure (e.g., server maintenance, microservices, relational databases such as PostgreSQL) and front-end website design/UI-UX. Maintain Authority to Operate (ATO) and require security documentation to keep systems compliant with applicable FISMA-level and other NIH requirements. Maintain, update, and develop Application Programming Interfaces (APIs) and cyberinfrastructure for secure, interoperable data exchange. Capabilities for homomorphic encryption and distributed learning. Demonstrate experience and technical expertise to address all aspects of informatics requirements listed above. K. Collaboration & Governance Establish a strong collaborative relationship with the NIH Data Centers, study teams, and Institutes/Centers to enable modifications as the studies evolve. Serve as a co-signatory of the Specimen/Material Transfer Agreements developed by the funding Institute/Center. Be eligible to receive a Certificate of Confidentiality, adhering to requirements for protecting sensitive participant information as set forth in 45 CFR Part 75.303(a), NIHGPS Chapter 8.3 and 15.2.1, and subsection 301(d) of the Public Health Service Act (see: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html). Comply with all applicable human subjects protection, ethical, privacy, and data security regulations. Submission Requirements Interested organizations must demonstrate and document in a submitted capability statement extensive experience across the technical areas above, and include specific information on: Experience — An outline of previous similar projects, specifically the techniques employed in the areas described above. Personnel — Name and professional qualifications of personnel with specific experience in the work requested and knowledge of/experience in biomedical research. Facilities — Availability and description of facilities and equipment required to conduct this type of work. The Government will assess the appropriateness of professional and technical personnel classifications and consider any other specific and relevant information that would improve evaluation of respondents. Organizations should demonstrate capability to administer and coordinate interrelated tasks effectively and in a timely manner. Supporting documentation may include contracts in which the organization performed equivalent tasks (Government and commercial), references (names, titles, phone numbers, and other identifying information), and awards or commendations. An organization that does not have all the listed expertise, may respond by listing organizations with which they intend to collaborate or have as subcontractors to fulfill the requirements. Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than October 20, 2026 at 1:00 PM EST. All capability statements should include: Company name and address Point of contact SAM.gov Unique Entity Identifier (UEI) Phone/fax/email NAICS Code(s) Business size and status Capability information responsive to the requirements and qualifications identified in this notice Type(s) of business, if any (e.g., small, Veteran-owned, service-disabled Veteran-owned, women-owned, 8(a), Small Disadvantaged Business (SDB), Historically Underutilized Business Zone (HUBZone)) NAICS Code: 541714 — Research and Development in Biotechnology (except Nanobiotechnology). SBA size standard: 1,000 employees or fewer. Submission Instructions Capability statements must be submitted electronically to: Shaun Rostad, Contract Specialist Email: shaun.rostad@nih.gov Secondary Point of Contact: Joshua T. Lazarus, Contract Specialist Email: josh.lazarus@nih.gov Submissions are due NO LATER THAN 1:00 p.m. EST on October 20, 2026. The subject line must include the Sources Sought Number. NIDA will not accept paper or faxed capability statements. Disclaimer THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement, nor does it constitute a solicitation or commitment by NIDA. The Government does not intend to award a contract based on responses under this announcement, nor otherwise pay for the preparation of any information submitted. Any proprietary information should be so marked. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Respondents should ensure their response is complete and sufficiently detailed to allow the Government to determine qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of information or provide feedback with respect to any information submitted. Based on the Government’s market research, it is the agency’s assessment that the services described herein do not appear to constitute commercial services as defined under RFO Subpart 2.1, and therefore, the agency does not currently intend to utilize RFO Part 12 Acquisition Procedures. However, if an interested party asserts that these services are in fact commercial in nature, it should respond to this requirement and provide supporting evidence demonstrating that the services meet the definition of commercial services as prescribed by the applicable regulations. | Market Research | 541714 | No Set-Aside | 10/01/2026 | 10/20/2026 | - | |
SOURCES SOUGHT NOTICE – No. 75N98026R00175 Title: Biobanking, Laboratory Analytics, and Associated Informatics Services for NIH Biorepositories Agency: National Institutes of Health (NIH) Description This is a SOURCES SOUGHT NOTICE. This is NOT a solicitation for proposals, proposal of abstracts or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified business sources and (2) whether commercial sources and services are available in the marketplace. Your response to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. This notice is issued to help determine the appropriate acquisition method including small business socioeconomic set aside possibilities and to determine the availability of commercial or non-commercial companies technically capable of meeting the Government's potential requirement. It is not construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Furthermore, it should be noted that any future solicitations that may be issued as a result of this notice, or in response to this requirement, may be issued using a different solicitation number from the one identified above. Purpose NIH is seeking capability statements from businesses, and subcontractors regarding their abilities to continue the work of the NIDA Center for Genetic Studies (NCGS) and the NIH Brain Development Cohorts (NBDC) Biobank, which supports the Adolescent Brain Cognitive Development (ABCD) Study, and HEALthy Brain and Child Development (HBCD) Study. Background NIH currently supports over 20 biorepositories across 10+ Institutes and Centers, with each individual biorepository storing several thousands to over 3.5 million samples. NIH biorepositories have stored, analyzed, and distributed millions of samples of biomaterials to enable broad investigations into the myriad of biological and environmental factors that affect health, development, and disease. These repositories typically: Receive, process, store, and biosamples from a wide range of biospecimen types (e.g. blood/derivatives, fluids, DNA/RNA, hair, cell lines, iPSCs, teeth, fecal matter, birth specimens and other tissues such as brain and other organs) at various temperature and storage conditions (e.g. -80C, liquid nitrogen; fresh, frozen, paraffin-embedded, formalin-fixed) at scales ranging from tens of thousands to several million specimens. Serve dozens to hundreds of research studies across the United States and abroad. Enable broad, controlled-access biomaterial sharing to meet specific research objectives that further our knowledge of health Anticipate continued growth in biospecimen and data volume over the life of the award. Scope of Work & Required Capabilities Capable vendors should provide examples from current or previous projects when responding to capabilities. A. Sample Management and Storage Maintain secure, humidity- and temperature-controlled storage and tracking for at least 3,500,000 biospecimens in accordance with Best Practices, Clinical and Laboratory Standards, and Good Laboratory Practice (GLP; 21 CFR 58) with expert quality control and assurance procedures. Document the maximum capacity that could be achieved to expand storage beyond the minimum requested. Destroy samples per regulatory and consent requirements when no longer needed. College of American Pathologists (CAP) Biorepository Accreditation preferred. Maintain positive chain of custody and resolve data/sample discrepancies (missing data, incorrect information, misdirected samples) through issue tracking and resolution, coordinating with relevant receiving/data management teams (e.g. sites, site monitors, study staff). Receive de-identified clinical, diagnostic, environmental, and phenotypic data alongside biospecimens from funded grants/contracts. Centrally manage and cost-effectively distribute biosamples to qualified investigators approved through established access programs. Provide studies with collection kits and supplies, including barcoded tubes with human-readable labels. Provide research staff training for ordering supplies and collecting samples. B. Data Curation and Management Develop and maintain SOPs for sample receipt, storage, processing, QC, and distribution. Receive de-identified clinical, diagnostic, environmental, and phenotypic data associated with biospecimens from funded grants/contracts. Maintain an internal relational database (e.g., using persistent identifiers such as RRIDs) linked to associated data and participant and sample identifiers, with computerized inventory management and accurate tracking of sample and data location. Register and track biospecimens via an internal relational database with sample IDs (RRID) linked to participant IDs and associated data in the Contractor's auditable LIMS, with computerized inventory management and accurate tracking of sample/data location. Clean, standardize, and harmonize clinical data with cross-disorder phenotypic knowledge (e.g. different diagnostic systems or criteria, such as RDOC, DSM, ICD), incorporating data from electronic health records when applicable. Transfer data and sample IDs to controlled-access repositories or Data Centers (e.g., dbGAP, NBDC Data Hub or program specific data repositories). C. Laboratory and Analytic Capabilities Demonstrate laboratory expertise appropriate to the repository's sample types, which may include molecular biology techniques (e.g., DNA/RNA extraction, cell line transformation/immortalization), rigorous quality control, and tissue/cell culture (isolation, scale-up, and banking of primary cells). Provide CLIA-certification status. Provide laboratory capabilities for, but not limited to: metabolic, hematologic, and/or clinical assays high-throughput genotyping, sequencing, and gene-expression analysis Mass spectrometry for proteomics and metabolomics Advanced genomic and cellular techniques such as short- and long-range sequencing, chromatin capture, ChIP-seq, Cut-and-Tag, HiC generation of iPSC/neural stem cell lines CRISPR/Cas9 gene editing Analysis of RNA and DNA from Formalin-Fixed Parafin-Embedded tissue Provide scientific and technical expertise to evaluate and respond to researcher-submitted requests for biospecimen availability. Demonstrate that lead investigators and support staff have relevant experience in biobanking, LIMS, and database management Store and/or process histopathological tissue samples. Isolate, scale up, and bank primary cells from diverse tissue samples. D. Informatics Requirements and Cyberinfrastructure Develop, or manage and enhance (if already existing), a biorepository web portal (front-end and back-end), supporting existing features and providing updates/improvements as requested, potentially including: Synchronizing sample availability data with a public- or investigator-facing sample explorer tool to streamline discovery of related data and biospecimens across repositories Showcase published research and provide lay summaries Advertise repository resources For existing resources, support all currently available features, with updates and improvements as requested Where in scope, develop outreach tools (e.g., an integrated chatbot or public-facing portal) to help users locate biomaterials/data and discover related resources across repositories Develop or maintain backend infrastructure (e.g., server maintenance, microservices, relational databases such as PostgreSQL) and front-end website design/UI-UX. Maintain Authority to Operate (ATO) and require security documentation to keep systems compliant with applicable FISMA-level and other NIH requirements. Maintain, update, and develop Application Programming Interfaces (APIs) and cyberinfrastructure for secure, interoperable data exchange. Capabilities for homomorphic encryption and distributed learning. Demonstrate experience and technical expertise to address all aspects of informatics requirements listed above. K. Collaboration & Governance Establish a strong collaborative relationship with the NIH Data Centers, study teams, and Institutes/Centers to enable modifications as the studies evolve. Serve as a co-signatory of the Specimen/Material Transfer Agreements developed by the funding Institute/Center. Be eligible to receive a Certificate of Confidentiality, adhering to requirements for protecting sensitive participant information as set forth in 45 CFR Part 75.303(a), NIHGPS Chapter 8.3 and 15.2.1, and subsection 301(d) of the Public Health Service Act (see: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-17-109.html). Comply with all applicable human subjects protection, ethical, privacy, and data security regulations. Submission Requirements Interested organizations must demonstrate and document in a submitted capability statement extensive experience across the technical areas above, and include specific information on: Experience — An outline of previous similar projects, specifically the techniques employed in the areas described above. Personnel — Name and professional qualifications of personnel with specific experience in the work requested and knowledge of/experience in biomedical research. Facilities — Availability and description of facilities and equipment required to conduct this type of work. The Government will assess the appropriateness of professional and technical personnel classifications and consider any other specific and relevant information that would improve evaluation of respondents. Organizations should demonstrate capability to administer and coordinate interrelated tasks effectively and in a timely manner. Supporting documentation may include contracts in which the organization performed equivalent tasks (Government and commercial), references (names, titles, phone numbers, and other identifying information), and awards or commendations. An organization that does not have all the listed expertise, may respond by listing organizations with which they intend to collaborate or have as subcontractors to fulfill the requirements. Based on preliminary market research, the Government has determined that the requirements described herein do not meet the definition of a commercial product or commercial service as defined in RFO 2.101, and therefore, RFO Part 12 procedures are not applicable to this requirement. However, if a capable vendor believes that these services or products qualify as commercial under FAR 2.101, the vendor may submit a written justification for the Contracting Officer's consideration. Such submissions must be provided to the Contracting Officer no later than October 20, 2026 at 1:00 PM EST. All capability statements should include: Company name and address Point of contact SAM.gov Unique Entity Identifier (UEI) Phone/fax/email NAICS Code(s) Business size and status Capability information responsive to the requirements and qualifications identified in this notice Type(s) of business, if any (e.g., small, Veteran-owned, service-disabled Veteran-owned, women-owned, 8(a), Small Disadvantaged Business (SDB), Historically Underutilized Business Zone (HUBZone)) NAICS Code: 541714 — Research and Development in Biotechnology (except Nanobiotechnology). SBA size standard: 1,000 employees or fewer. Submission Instructions Capability statements must be submitted electronically to: Shaun Rostad, Contract Specialist Email: shaun.rostad@nih.gov Secondary Point of Contact: Joshua T. Lazarus, Contract Specialist Email: josh.lazarus@nih.gov Submissions are due NO LATER THAN 1:00 p.m. EST on October 20, 2026. The subject line must include the Sources Sought Number. NIDA will not accept paper or faxed capability statements. Disclaimer THIS IS NOT A REQUEST FOR PROPOSALS. This notice is for information and planning purposes only and does not commit the Government to any contractual agreement, nor does it constitute a solicitation or commitment by NIDA. The Government does not intend to award a contract based on responses under this announcement, nor otherwise pay for the preparation of any information submitted. Any proprietary information should be so marked. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Respondents should ensure their response is complete and sufficiently detailed to allow the Government to determine qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of information or provide feedback with respect to any information submitted. Based on the Government’s market research, it is the agency’s assessment that the services described herein do not appear to constitute commercial services as defined under RFO Subpart 2.1, and therefore, the agency does not currently intend to utilize RFO Part 12 Acquisition Procedures. However, if an interested party asserts that these services are in fact commercial in nature, it should respond to this requirement and provide supporting evidence demonstrating that the services meet the definition of commercial services as prescribed by the applicable regulations. | Market Research | 541714 | No Set-Aside | 09/28/2026 | 10/20/2026 | - |
Additional Details
Solicitation Number
75N92026R00007
Archive Date
Apr 18, 2026
Office Address
BETHESDA, MD, 20892